Risperdal is a prescription medication manufactured by Ortho-McNeil-Janssen Pharmaceuticals, a subsidiary of the Johnson & Johnson Co. Risperdal use has been linked with a condition called gynecomastia, where young boys develop breast tissue and in some cases experience nipple pain or discharge.
The FDA approved Risperdal in 1993 for the treatment of schizophrenia, acute mania, and bipolar disorders. Risperdal has also been prescribed as treatment for conditions for which it was neither tested nor approved by the FDA. The drug was prescribed to children prior to its being approved by the FDA for children.
Risperdal is often prescribed to minors to treat autism, bipolar disorder, or schizophrenia. There is reason to believe that Risperdal increases patients levels of prolactin, a hormone that stimulates breast development in women and can cause boys to develop female-type breast tissue.
Several hundred lawsuits have been filed against Johnson &Johnson on behalf of men adversely affected by the drug. The lawsuits include individual claims and class action suits, many of which have been settled in the plaintiffs’ favor.
Plaintiff’s allege that the drug maker concealed or downplayed side effects, including:
In November 2013, Johnson & Johnson agreed to resolve criminal and civil investigations into the marketing of Risperdal and other medications and pay more than $2.2 billion in fines for misbranding Risperdal for unapproved uses and for paying kickbacks to physicians and nursing care facilities.
For assistance with your Risperdal case, click here to find Risperdal attorneys near you or find attorneys in a different state.